Printer Friendly

SPECTRASCIENCE LASER DIAGNOSTIC SYSTEM USED IN SUCCESSFUL CORONARY PROCEDURE AT CLEVELAND CLINIC

 SPECTRASCIENCE LASER DIAGNOSTIC SYSTEM USED IN SUCCESSFUL
 CORONARY PROCEDURE AT CLEVELAND CLINIC
 MINNEAPOLIS, Nov. 9 /PRNewswire/ -- SpectraScience, Inc. (NASDAQ: SPSC), announced today that its diagnostic system, which uses laser-induced fluorescence, was used successfully in a coronary procedure last week at the Cleveland Clinic.
 As part of a clinical study being conducted through agreement with the Cleveland Clinic Foundation, a team of physicians used the SpectraScience system to identify and characterize a patient's coronary artery disease. Similar procedures had been conducted on peripheral arteries, but this marks the first use of the system to diagnose a coronary condition.
 "This coronary procedure is a significant milestone for SpectraScience," said Daryl F. Yurek, chairman and chief executive officer of the company. "The cardiology department at Cleveland Clinic has been involved in clinical studies of our product, and they are enthusiastic about the results. We expect to conclude this phase of trials in December, and to submit a U.S. Food and Drug Administration (FDA) 510(k) application by the end of 1992."
 SpectraScience designs, develops, manufactures and markets laser- enhanced systems for the diagnosis and treatment of cardiovascular disease. The laser diagnostic system currently is the main focus of the company's development efforts. SpectraScience is based in Minneapolis.
 -0- 11/09/92
 /CONTACT: John Swenson of Swenson Falker Eilertson Inc., 612-371-0000, for SpectraScience; or Tom Ahmann of SpectraScience, 612-559-4000/
 (SPSC) CO: SpectraScience, Inc.; Cleveland Clinic ST: Minnesota, Ohio IN: MTC SU:


KH -- MN006 -- 8691 11/09/92 12:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 9, 1992
Words:247
Previous Article:HORN & HARDART RECEIVES CONSENTS TO LOWER CONVERSION PRICE ON 7-1/2 PERCENT CONVERTIBLE SUBORDINATED DEBENTURES
Next Article:APPLIX ANNOUNCES TWO EXECUTIVE APPOINTMENTS: EXPANSION OF EXECUTIVE MANAGEMENT TEAM CORRESPONDS WITH COMPANY GROWTH
Topics:


Related Articles
GV MEDICAL AIMS TO DEVELOP DIAGNOSTIC SYSTEM AS STAND-ALONE PRODUCT; ANNOUNCES GRABEK RESIGNATION
CLEVELAND CLINIC DOCTORS REPORT THAT GV MEDICAL DEVICE SUCCESSFULLY IDENTIFIES TISSUE TYPES
GV MEDICAL BEGINS CLINICAL TRIALS OF LASER DIAGNOSTIC SYSTEM
SPECTRASCIENCE REPORTS THIRD QUARTER RESULTS
SPECTRASCIENCE GETS $1.1 MILLION FROM WARRANT EXERCISE
SPECTRASCIENCE GETS TOTAL OF $3,252,998 FROM WARRANT EXERCISE
SPECTRASCIENCE RECEIVES ORDERS FOR NEW DIAGNOSTIC SYSTEM
SPECTRASCIENCE REPORTS FIRST QUARTER RESULTS, CLINICAL PROGRESS
COMPANY WILL RESUME CLINICAL TRIALS AS A RESULT OF PRODUCT ENHANCEMENTS; PRODUCT COMMERCIALIZATION ANTICIPATED IN 1994; DIRECTOR RESIGNS
SPECTRASCIENCE FILES 510K WITH FOOD AND DRUG ADMINISTRATION

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters